168 related articles for article (PubMed ID: 24716981)
21. Predictive factors and pattern of central lymph node metastasis in unilateral papillary thyroid carcinoma.
Ji YB; Yoo HS; Song CM; Park CW; Lee CB; Tae K
Auris Nasus Larynx; 2016 Feb; 43(1):79-83. PubMed ID: 26441368
[TBL] [Abstract][Full Text] [Related]
22. Influence of presence/absence of thyroid gland on the cutoff value for thyroglobulin in lymph-node aspiration to detect metastatic papillary thyroid carcinoma.
Zhao H; Wang Y; Wang MJ; Zhang ZH; Wang HR; Zhang B; Guo HQ
BMC Cancer; 2017 Apr; 17(1):296. PubMed ID: 28454525
[TBL] [Abstract][Full Text] [Related]
23. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma.
Shin JH; Ha TK; Park HK; Ahn MS; Kim KH; Bae KB; Kim TH; Choi CS; Kim TK; Bae SK; Kim SH
Int J Surg; 2013; 11(9):944-7. PubMed ID: 23820062
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins.
Mseddi M; Ben Mansour R; Gouiia N; Mnif F; Bousselaa R; Abid M; Boudaouara T; Attia H; Lassoued S
Adv Med Sci; 2017 Mar; 62(1):45-51. PubMed ID: 28187375
[TBL] [Abstract][Full Text] [Related]
25. Multifocal Papillary Thyroid Cancer Increases the Risk of Central Lymph Node Metastasis.
Al Afif A; Williams BA; Rigby MH; Bullock MJ; Taylor SM; Trites J; Hart RD
Thyroid; 2015 Sep; 25(9):1008-12. PubMed ID: 26161997
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review.
Aragon Han P; Weng CH; Khawaja HT; Nagarajan N; Schneider EB; Umbricht CB; Witwer KW; Zeiger MA
Thyroid; 2015 Dec; 25(12):1322-9. PubMed ID: 26414548
[TBL] [Abstract][Full Text] [Related]
27. Hashimoto's Thyroiditis Does Not Affect Ultrasonographical, Cytological, and Histopathological Features in Patients with Papillary Thyroid Carcinoma.
Baser H; Ozdemir D; Cuhaci N; Aydin C; Ersoy R; Kilicarslan A; Cakir B
Endocr Pathol; 2015 Dec; 26(4):356-64. PubMed ID: 26481630
[TBL] [Abstract][Full Text] [Related]
28. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
29. Surgical extent of central lymph node dissection in clinically node-negative papillary thyroid cancer.
Kim WW; Park HY; Jung JH
Head Neck; 2013 Nov; 35(11):1616-20. PubMed ID: 23322499
[TBL] [Abstract][Full Text] [Related]
30. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status.
Mussazhanova Z; Matsuda K; Naruke Y; Mitsutake N; Stanojevic B; Rougounovitch T; Saenko V; Suzuki K; Nishihara E; Hirokawa M; Ito M; Nakashima M
Histopathology; 2013 Nov; 63(5):726-34. PubMed ID: 24004175
[TBL] [Abstract][Full Text] [Related]
31. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
32. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
33. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
34. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
[TBL] [Abstract][Full Text] [Related]
35. The Clinical Relevance of Psammoma Body and Hashimoto Thyroiditis in Papillary Thyroid Carcinoma: A Large Case-control Study.
Cai YF; Wang QX; Ni CJ; Guo GL; Li Q; Wang OC; Wu L; Du HY; You J; Zhang XH
Medicine (Baltimore); 2015 Nov; 94(44):e1881. PubMed ID: 26554782
[TBL] [Abstract][Full Text] [Related]
36. Robot-assisted Sistrunk's operation, total thyroidectomy, and neck dissection via a transaxillary and retroauricular (TARA) approach in papillary carcinoma arising in thyroglossal duct cyst and thyroid gland.
Byeon HK; Ban MJ; Lee JM; Ha JG; Kim ES; Koh YW; Choi EC
Ann Surg Oncol; 2012 Dec; 19(13):4259-61. PubMed ID: 23070784
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.
Balta AZ; Filiz AI; Kurt Y; Sucullu I; Yucel E; Akin ML
Med Oncol; 2012 Jun; 29(2):734-41. PubMed ID: 21547408
[TBL] [Abstract][Full Text] [Related]
38. Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer.
Qu N; Zhang L; Wu WL; Ji QH; Lu ZW; Zhu YX; Lin DZ
Tumour Biol; 2016 Jul; 37(7):8783-9. PubMed ID: 26743781
[TBL] [Abstract][Full Text] [Related]
39. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link?
Unger P; Ewart M; Wang BY; Gan L; Kohtz DS; Burstein DE
Hum Pathol; 2003 Aug; 34(8):764-9. PubMed ID: 14506636
[TBL] [Abstract][Full Text] [Related]
40. Breach of the thyroid capsule and lymph node capsule in node-positive papillary and medullary thyroid cancer: Different biology.
Machens A; Dralle H
Eur J Surg Oncol; 2015 Jun; 41(6):766-72. PubMed ID: 25468749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
